论文部分内容阅读
近20年来,国内外急性心肌梗死(AMI)临床上最重要的进展是再灌注治疗,即冠状动脉再通,恢复受损心肌的血流供应。能够达到这个目的治疗方法包括冠状动脉溶栓、静脉溶栓、经皮冠状动脉腔内成形术(PTCA)、冠状动脉内支架等。在我国应用最广的是静脉溶栓。在缺乏高新医疗设备和介入技术的医疗单位,在经济尚不发达地区和收入不高的人群,采取静脉溶栓不失为较好的、符合现代要求的治疗AMI的一种方法。据估计,我国每年约有数以万计的AMI患者接受静脉溶栓治疗。治疗效果如何,自然成为大家关注的问题。溶栓治疗的近期效果,国内外文献有不少报道。国外的几组大规模、随机、双盲-安慰剂对照临床试验,例如1986年发表的意大利链激
In the recent 20 years, the most clinically important progress of acute myocardial infarction (AMI) both at home and abroad has been reperfusion therapy, namely, coronary recanalization and restoration of blood supply to damaged myocardium. Therapeutic approaches that can be achieved for this purpose include coronary thrombolysis, intravenous thrombolysis, percutaneous transluminal coronary angioplasty (PTCA), coronary stents and the like. In our country is the most widely used intravenous thrombolysis. In the absence of high-tech medical equipment and interventional medical units, in economically underdeveloped areas and low income people, the adoption of intravenous thrombolysis is a better, meet the modern requirements of a method of treatment of AMI. It is estimated that tens of thousands of AMI patients receive intravenous thrombolysis every year in our country. How the treatment effect, naturally become everyone’s concern. The immediate effect of thrombolytic therapy, there are many reports at home and abroad. Several large-scale, randomized, double-blind, placebo-controlled clinical trials abroad, such as the Italian chainburst published in 1986